144 related articles for article (PubMed ID: 28849031)
41. TRPC4α and TRPC4β Similarly Affect Neonatal Cardiomyocyte Survival during Chronic GPCR Stimulation.
Kirschmer N; Bandleon S; von Ehrlich-Treuenstätt V; Hartmann S; Schaaf A; Lamprecht AK; Miranda-Laferte E; Langsenlehner T; Ritter O; Eder P
PLoS One; 2016; 11(12):e0168446. PubMed ID: 27992507
[TBL] [Abstract][Full Text] [Related]
42. Syringin prevents cardiac hypertrophy induced by pressure overload through the attenuation of autophagy.
Li F; Zhang N; Wu Q; Yuan Y; Yang Z; Zhou M; Zhu J; Tang Q
Int J Mol Med; 2017 Jan; 39(1):199-207. PubMed ID: 27959392
[TBL] [Abstract][Full Text] [Related]
43. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.
Nakamura TY; Iwata Y; Arai Y; Komamura K; Wakabayashi S
Circ Res; 2008 Oct; 103(8):891-9. PubMed ID: 18776042
[TBL] [Abstract][Full Text] [Related]
44. Normalization of the calcineurin pathway underlies the regression of hypertensive hypertrophy induced by Na+/H+ exchanger-1 (NHE-1) inhibition.
Ennis IL; Garciarena CD; Escudero EM; Pérez NG; Dulce RA; Camilión de Hurtado MC; Cingolani HE
Can J Physiol Pharmacol; 2007; 85(3-4):301-10. PubMed ID: 17612638
[TBL] [Abstract][Full Text] [Related]
45. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy.
Dong DL; Chen C; Huo R; Wang N; Li Z; Tu YJ; Hu JT; Chu X; Huang W; Yang BF
Hypertension; 2010 Apr; 55(4):946-52. PubMed ID: 20177001
[TBL] [Abstract][Full Text] [Related]
46. Isorhamnetin protects against cardiac hypertrophy through blocking PI3K-AKT pathway.
Gao L; Yao R; Liu Y; Wang Z; Huang Z; Du B; Zhang D; Wu L; Xiao L; Zhang Y
Mol Cell Biochem; 2017 May; 429(1-2):167-177. PubMed ID: 28176246
[TBL] [Abstract][Full Text] [Related]
47. Celecoxib prevents pressure overload-induced cardiac hypertrophy and dysfunction by inhibiting inflammation, apoptosis and oxidative stress.
Zhang C; Wang F; Zhang Y; Kang Y; Wang H; Si M; Su L; Xin X; Xue F; Hao F; Yu L; Xu J; Liu Y; Xue M
J Cell Mol Med; 2016 Jan; 20(1):116-27. PubMed ID: 26512452
[TBL] [Abstract][Full Text] [Related]
48. Hyperhomocysteinemia Promotes Cardiac Hypertrophy in Hypertension.
Deng Y; Li Z; An X; Fan R; Wang Y; Li J; Yang X; Liao J; Xia Y
Oxid Med Cell Longev; 2022; 2022():1486157. PubMed ID: 36046692
[TBL] [Abstract][Full Text] [Related]
49. Leech extract: A candidate cardioprotective against hypertension-induced cardiac hypertrophy and fibrosis.
Wang CH; Pandey S; Sivalingam K; Shibu MA; Kuo WW; Yu-LanYeh ; Viswanadha VP; Lin YC; Liao SC; Huang CY
J Ethnopharmacol; 2021 Jan; 264():113346. PubMed ID: 32896627
[TBL] [Abstract][Full Text] [Related]
50. Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca2+-ATPase activity in rat cardiac pressure-overload hypertrophy.
Jiang QJ; Xu G; Mao FF; Zhu YF
J Zhejiang Univ Sci B; 2006 Mar; 7(3):228-34. PubMed ID: 16502511
[TBL] [Abstract][Full Text] [Related]
51. Cardiac-Specific EPI64C Blunts Pressure Overload-Induced Cardiac Hypertrophy.
Zhu X; Fang J; Gong J; Guo JH; Zhao GN; Ji YX; Liu HY; Wei X; Li H
Hypertension; 2016 May; 67(5):866-77. PubMed ID: 27021007
[TBL] [Abstract][Full Text] [Related]
52. Long-term administration of pyridostigmine attenuates pressure overload-induced cardiac hypertrophy by inhibiting calcineurin signalling.
Lu Y; Zhao M; Liu JJ; He X; Yu XJ; Liu LZ; Sun L; Chen LN; Zang WJ
J Cell Mol Med; 2017 Sep; 21(9):2106-2116. PubMed ID: 28296184
[TBL] [Abstract][Full Text] [Related]
53. Mesenchymal Stem Cells and Cardiomyocytes Interplay to Prevent Myocardial Hypertrophy.
Cai B; Tan X; Zhang Y; Li X; Wang X; Zhu J; Wang Y; Yang F; Wang B; Liu Y; Xu C; Pan Z; Wang N; Yang B; Lu Y
Stem Cells Transl Med; 2015 Dec; 4(12):1425-35. PubMed ID: 26586774
[TBL] [Abstract][Full Text] [Related]
54. Leptin-induced cardiomyocyte hypertrophy reveals both calcium-dependent and calcium-independent/RhoA-dependent calcineurin activation and NFAT nuclear translocation.
Rajapurohitam V; Izaddoustdar F; Martinez-Abundis E; Karmazyn M
Cell Signal; 2012 Dec; 24(12):2283-90. PubMed ID: 22917533
[TBL] [Abstract][Full Text] [Related]
55. Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy.
Zou Y; Hiroi Y; Uozumi H; Takimoto E; Toko H; Zhu W; Kudoh S; Mizukami M; Shimoyama M; Shibasaki F; Nagai R; Yazaki Y; Komuro I
Circulation; 2001 Jul; 104(1):97-101. PubMed ID: 11435345
[TBL] [Abstract][Full Text] [Related]
56. Tamarixetin protects against cardiac hypertrophy via inhibiting NFAT and AKT pathway.
Fan C; Li Y; Yang H; Cui Y; Wang H; Zhou H; Zhang J; Du B; Zhai Q; Wu D; Chen X; Guo H
J Mol Histol; 2019 Aug; 50(4):343-354. PubMed ID: 31111288
[TBL] [Abstract][Full Text] [Related]
57. Arctiin protects against cardiac hypertrophy through inhibiting MAPKs and AKT signaling pathways.
Li J; Yuan YP; Xu SC; Zhang N; Xu CR; Wan CX; Ren J; Zeng XF; Tang QZ
J Pharmacol Sci; 2017 Nov; 135(3):97-104. PubMed ID: 29108833
[TBL] [Abstract][Full Text] [Related]
58. In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy.
He T; Chen L; Chen Y; Han Y; Yang WQ; Jin MW
Cardiovasc Drugs Ther; 2012 Apr; 26(2):109-20. PubMed ID: 22183794
[TBL] [Abstract][Full Text] [Related]
59. Rosuvastatin prevents pressure overload‑induced myocardial hypertrophy via inactivation of the Akt, ERK1/2 and GATA4 signaling pathways in rats.
Xu X; Zhang L; Liang J
Mol Med Rep; 2013 Aug; 8(2):385-92. PubMed ID: 23799547
[TBL] [Abstract][Full Text] [Related]
60. TAK1 Regulates Myocardial Response to Pathological Stress via NFAT, NFκB, and Bnip3 Pathways.
Li L; Chen Y; Li J; Yin H; Guo X; Doan J; Molkentin JD; Liu Q
Sci Rep; 2015 Nov; 5():16626. PubMed ID: 26564789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
